"Effect of Licorice in treatment of Nonalcoholic Fatty Liver Disease"

Effects of licorice root on metabolic factors, hepatic enzymes, hepatic steatosis, and oxidative stress in obese women with nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200903048603N1

Enrollment

Registered

2020-10-04

Start date

2019-05-22

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Licorice root powder 1000 mg / day. Intervention 2: Control group: Maltodextrin 1000 mg / day.

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Lack of acute or chronic Liver disease Lack of using of Tabacco or alcohol Lack of cardiovascular diseases, and Hypertension Lack of Diabetes Mellitus, Kidney diseases, Malignancy, Viral Hepatitis, Wilson disease Hemochromatosis, Cystic fibrosis and Autoimmune diseases Lack of using of any approved therapies known to have potential benefit in NAFLD control within the previous 3 months Lack of using of Hepatotoxic drugs within the past 6 months

Exclusion criteria

Exclusion criteria: Lack of Fatty Liver in Ultrasonography

Design outcomes

Primary

Measure	Time frame
Liver steatosis. Timepoint: Previous of intervention and 3 months after of initiating of study. Method of measurement: Ultrasonography.	—

Secondary

Measure	Time frame
Malondialdehyde. Timepoint: Previous of intervention and 3 months after of initiating of study. Method of measurement: Analysis of serum samples.;Alanine aminotransferase. Timepoint: Previous of intervention and 3 months after initiating study. Method of measurement: Analysis of serum samples.;Aspartate aminotransferas. Timepoint: Previous of intervention and 3 months after of initiating study. Method of measurement: Analysis of serum samples.;Gama gluthamyl transpeptidase. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Analysis os serum samples.;Lipid profile. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Analysis of serum samples.;Fasting blood sugar. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Analysis of serum samples.;Serum insulin. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Analysis of serum samples.;HOMA- IR. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: ( serum insulin × Fasting blood sugar) ÷ 405.;Wheight. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Using scale (kg).;BMI (Body mass index). Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Wheight(kg) ÷ (Height (m) × Height (m) ).;Liver steatosis. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Ultrasonography.	—

Measure

Time frame

Malondialdehyde. Timepoint: Previous of intervention and 3 months after of initiating of study. Method of measurement: Analysis of serum samples.;Alanine aminotransferase. Timepoint: Previous of intervention and 3 months after initiating study. Method of measurement: Analysis of serum samples.;Aspartate aminotransferas. Timepoint: Previous of intervention and 3 months after of initiating study. Method of measurement: Analysis of serum samples.;Gama gluthamyl transpeptidase. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Analysis os serum samples.;Lipid profile. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Analysis of serum samples.;Fasting blood sugar. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Analysis of serum samples.;Serum insulin. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Analysis of serum samples.;HOMA- IR. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: ( serum insulin × Fasting blood sugar) ÷ 405.;Wheight. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Using scale (kg).;BMI (Body mass index). Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Wheight(kg) ÷ (Height (m) × Height (m) ).;Liver steatosis. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Ultrasonography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPouya Rostamizadeh

Shiraz University of Medical Sciences

Pouyarostamizadeh@gmail.com+98 71 3725 1007

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026